Results 31 to 40 of about 27,891 (280)

Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients

open access: yesFrontiers in Pharmacology, 2022
Leukotrienes are important pro-inflammatory lipid mediators derived from the arachidonic acid metabolism. In particular, cysteinyl leukotrienes, namely LTC4, LTD4, and LTE4 are involved in many of the principal features of asthma, while more recently ...
M. Camera   +3 more
semanticscholar   +1 more source

Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol

open access: yesTrials, 2022
Background The coronavirus disease 2019 (COVID-19) pandemic continues to affect the globe. After 18 months of the SARS-CoV-2 emergence, clinicians have clearly defined a subgroup of patients with lasting, disabling symptoms.
Francisco Mera-Cordero   +10 more
semanticscholar   +1 more source

Pediatric Asthma: Where Has Montelukast Gone?

open access: yesApplied Sciences, 2023
At its introduction in the management of pediatric asthma, montelukast was regarded as a potentially revolutionary drug due to its mechanism of action and easy clinical applicability.
Marco Maglione   +3 more
doaj   +1 more source

Adverse Drug Reactions (ADRs) of Montelukast in Children

open access: yesChildren, 2022
Montelukast is a leukotriene receptor antagonist (LTRA) commonly prescribed for asthma, allergic rhinitis and sleep-related breathing disorders. Recently, some studies have reported several adverse events, such as neuropsychiatric disorders and sleep ...
Abdullah Al-Shamrani   +8 more
semanticscholar   +1 more source

Montelukast: Chronic Urticaria [PDF]

open access: yesHospital Pharmacy, 2015
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or
Joyce A. Generali, Dennis J. Cada
openaire   +3 more sources

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator

open access: yesViruses, 2022
Coronaviruses (CoVs) consist of a large group of RNA viruses causing various diseases in humans and in lots of animals. Human coronavirus (HCoV) OC43, the prototype of beta-coronavirus discovered in the 1960s, has been circulating in humans for long time,
Yongkang Chen   +3 more
semanticscholar   +1 more source

Montelukast and Nightmares: Further Characterisation Using Data from VigiBase

open access: yesDrug Safety, 2022
Montelukast is a medicine indicated for use in asthma. Psychiatric disorders including nightmares have not been described in clinical trials but during recent years have been included in the product information as having been reported post-marketing ...
Sarah Watson   +4 more
semanticscholar   +1 more source

Tailored second line therapy in asthmatic children with the arginine-16 genotype [PDF]

open access: yes, 2012
The arginine-16 beta-2 receptor genotype confers increased susceptibility to exacerbations in asthmatic children taking regular long acting beta-2 agonists.
Aziz   +27 more
core   +1 more source

Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID‐19

open access: yesJournal of Medical Virology, 2021
The inflammatory/anti‐inflammatory balance has an important role in the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (coronavirus disease [COVID‐19]) infection, which has affected over 200 million people since it first ...
Buğra Kerget   +3 more
semanticscholar   +1 more source

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma [PDF]

open access: yes, 2011
Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta2-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be considered ...
Adams   +207 more
core   +1 more source

Home - About - Disclaimer - Privacy